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Abstract
Objective:  To  determine  the  frequency  of  prescriptions  of  off-label  drugs  and  drugs  not
approved for  pediatric  use  in  primary  health  care  in  medium-sized  municipality  of  Rio  Grande
do Sul,  Brazil.
Methods:  Cross-sectional  study  with  retrospective  data  collection,  which  analyzed  prescrip-
tions issued  to  326  patients  from  August  to  December/2012  in  two  basic  health  units  in  the  city
of Viamão,  state  of  Rio  Grande  do  Sul.  It  included  all  prescriptions  of  patients  whose  medical
records  or  service  records  were  available  and  complete  in  relation  to  the  date  of  presence,
weight and  date  of  birth.  Off-label  prescriptions  were  those  which,  in  relation  to  the  drug
leaﬂet, showed  dose  different  the  recommended  range,  frequency  of  prescription  and/or  dif-
ferent form  of  administration  and  younger  age  than  the  indicated  range.  Descriptive  statistics
with absolute  frequencies,  means  and  standard  deviations  were  used.
Results:  During  the  study  period,  a  total  of  731  drug  prescriptions  were  issued  and  the  frequency
of off-label  medications  prescribed  was  31.7%,  especially  antihistamines  and  antiasthmatics
(32.3% and  31.5%,  respectively).  The  main  type  of  off-label  prescription  was  dose  (38.8%),
followed by  age  range  (31.5%)  and  frequency  of  administration  (29.3%).  Regarding  the  dose  off-
label prescription,  overdose  was  more  frequent  (93.3%)  than  the  underdose  (6.7%).  Prescriptions
of unapproved  drugs  were  not  identiﬁed.
Conclusions:  The  study  showed  that  off  label  prescription  is  common  in  both  assessed  units.
The observed  percentage  of  off  label  prescription  was  higher  than  that  reported  by  European
studies carried  out  in  primary  care.  On  the  other  hand,  the  prescription  of  drugs  not  approved
for children  was  not  observed.
©  2015  Sociedade  de  Pediatria  de  Sa˜o  Paulo.  Published  by  Elsevier  Editora  Ltda.  This  is  an  open
access article  under  the  CC  BY  license  (https://creativecommons.org/licenses/by/4.0/).
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Frequência  de  prescric¸ões  de  medicamentos  off  label  e  não  licenciados
para  pediatria  na  atenc¸ão primária  à  saúde  em  município  do  sul  do  Brasil
Resumo
Objetivo:  Determinar  a  frequência  de  prescric¸ões  de  medicamentos  off  label  e  não  licenciados
para pediatria  na  atenc¸ão  primária  à  saúde  em  município  de  médio  porte  do  Rio  Grande  do  Sul,
Brasil.
Métodos: Estudo  transversal,  com  coleta  retrospectiva,  que  analisou  prescric¸ões  a  326
pacientes emitidas  de  agosto  a  dezembro  de  2012  em  dois  postos  de  saúde  do  município  de
Viamão. Foram  incluídas  todas  as  receitas  de  pacientes  cujos  prontuários  ou  ﬁchas  de  atendi-
mento estivessem  disponíveis  e  completos  em  relac¸ão  à  data  de  atendimento,  peso  e  data  de
nascimento.  Foram  classiﬁcadas  como  prescric¸ões  off  label  aquelas  que,  em  relac¸ão  à  bula
do medicamento,  apresentavam  dose  diferente  da  recomendada,  frequência  de  prescric¸ão
e/ou forma  de  administrac¸ão  diferente  e  idade  inferior  àquela  indicada.  Foi  usada  estatística
descritiva,  com  frequências  absolutas,  médias  e  desvio  padrão.
Resultados:  Durante  o  período  estudado  houve  a  prescric¸ão  de  731  medicamentos  e  houve
frequência  de  31,7%  de  medicamentos  prescritos  off  label,  especialmente  anti-histamínicos  e
antiasmáticos  (32,3%  e  31,5%,  respectivamente).  O  principal  tipo  de  prescric¸ão  off  label  foi
dose (38,8%),  seguida  de  idade  (31,5%)  e  de  frequência  de  administrac¸ão  (29,3%).  Com  relac¸ão
à prescric¸ão  off  label  de  dose,  foi  mais  frequente  a  sobredose  (93,3%)  do  que  a  subdose  (6,7%).
Não foram  encontradas  prescric¸ões  de  medicamentos  não  licenciados.
Conclusões:  O  estudo  mostrou  que  a  prescric¸ão  off  label  é  comum  nas  duas  unidades  estudadas.
O percentual  de  prescric¸ão  off  label  observado  foi  superior  ao  relatado  por  estudos  europeus
feitos na  atenc¸ão  primária.  Por  outro  lado,  não  foi  observada  prescric¸ão  de  medicamentos  não
licenciados  para  crianc¸as.
© 2015  Sociedade  de  Pediatria  de  Sa˜o  Paulo.  Publicado  por  Elsevier  Editora  Ltda.  Este  é  um  artigo
Open Access  sob  a  licença  CC  BY  (https://creativecommons.org/licenses/by/4.0/deed.pt).
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introduction
onsidering  the  lack  of  drugs  for  use  in  children,  espe-
ially  those  under  2  years  of  age,  the  off-label  prescription
rugs  have  become  a  routine  practice  both  in  hospitals  and
mbulatory  and  brings  doubts  to  prescribers  and  providers
egarding  the  beneﬁt  to  the  pediatric  patient.1,2
The  term  ‘‘off-label’’  refers  to  drugs  prescribed  in  differ-
nt  manner  than  that  directed  in  the  instructions  or  ofﬁcial
ompendia  in  relation  to  dose,  indication,  age  group,  dosing
nterval,  or  form  of  administration.3 Off-label  prescription
s  not  illegal;  it  is  not  necessarily  incorrect  and  is  present
n  several  pediatric  protocols.  The  quality  of  drug  ther-
py  is  not  necessarily  related  to  the  licensing  status  of  the
rug.  However,  there  are  several  clinical,  ethical,  and  safety
actors  that  should  be  considered  and  there  are  no  guide-
ines  to  assist  off-label  prescription.  The  decision  on  this
ype  of  prescription  should  be  assessed  according  to  clini-
al  indication,  treatment  options,  and  risk-beneﬁt  analysis.
oreover,  it  must  obtain  the  patient’s  or  guardian  con-
ent,  taking  care  to  avoid  exposing  children  to  unnecessary
isks.4
Regarding  the  concept  of  unlicensed  medicine,  some
uthors  consider  that  it  refers  to  drugs  that  are  unregistered
n  the  surveillance  agency,  or  are  extemporaneous  prepa-
ations,  or  drugs  containing  non-pharmacological  chemical
ngredients  used  with  therapeutic  purpose.5--8 Ferreira  et  al.
xtend  the  concept  of  unlicensed  to  registered  drugs  that
re  contraindicated  for  children.9
2
u
w
pThere  are  studies  that  characterize  the  extent  of  off-
abel  prescribing  in  pediatric  hospitals  in  Brazil,9--11 but  little
s  known  of  outpatient  prescription  in  primary  care.  This
tudy  aims  to  ﬁll  this  gap,  determine  the  frequency  of  pre-
cription  of  off-label  and  unlicensed  drugs  for  pediatrics,  to
upport  the  development  of  actions  to  promote  rational  use
f  drugs.
ethod
ross-sectional  study  with  retrospective  data  collection,
pproved  by  the  Research  Ethics  Committee  of  the  Uni-
ersidade  Federal  do  Rio  Grande  do  Sul  (No.  214  535)  and
uthorized  by  the  Municipal  Secretary  of  Health  of  Viamão.
ata  collection  was  performed  in  two  basic  health  units:
amily  Health  Strategy  (FHS)  Itapuã  and  Reference  Unit  (RU)
omba  Sabão,  Viamão.  Viamão  is  a  city  of  the  metropolitan
rea  located  20.6km  from  the  capital  Porto  Alegre,  with  an
rea  of  1494.26km2 and  239,384  inhabitants,  according  to
he  Demographic  Census  of  the  Brazilian  Institute  of  Geog-
aphy  and  Statistics  (IBGE)  2010.12
Sample  size  calculation  was  performed  considering  3759
ediatric  consultations  in  health  facilities  involved  dur-
ng  a  period  of  ﬁve  months  (August--December  2012).  A
0%  expected  frequency  of  off-label  prescription  drugs  was
sed.4--8,13--16 To  a  95%  conﬁdence  interval,  a  20%+5%  range
as  considered.  Thus,  it  was  estimated  that  at  least  231
rescriptions  should  be  evaluated.
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DPrescriptions  of  off-label  drugs  and  drugs  not  approved  for  p
Copies  of  prescriptions  retained  in  the  unit  dispen-
sary  after  dispensing  were  evaluated,  with  medication  of
patients  under  the  age  of  12  attended  by  pediatricians  of
the  respective  health  units,  from  August  to  December  2012.
We  excluded  prescriptions  for  patients  not  linked  to  the
unit.  Unit  user  prescriptions  whose  medical  records  were  not
found  or  were  incomplete  regarding  the  variables  of  interest
were  not  considered.
Prescription  data  were  recorded  on  a  speciﬁc  table  and
supplemented  with  information  from  medical  records  or
patient’s  chart.  The  variables  of  interest  related  to  the
patient  (age,  sex,  and  weight)  and  prescriptions  (total
items,  prescription  drugs,  presentations,  dosage  form,  route
of  administration,  frequency  of  administration,  and  dose)
were  recorded.
For  data  analysis  patients  were  divided  into  four  groups
according  to  age:  infants  (0--2  years),  preschoolers  (>2--7
years),  schoolers  (>7--10  years),  and  adolescents  (>10--12
years).  The  prescribed  drugs  were  classiﬁed  according  to
ANVISA  Electronic  Labeling  (Bulário  Eletrônico  da  Agência
Nacional  de  Vigilância  Sanitária)17 and,  in  the  absence  of
information  on  this  site,  instructions  provided  by  the  manu-
facturer  into  three  classiﬁcations:  according  to  speciﬁcation
(age,  dose,  frequency  of  administration  and  form  of  admin-
istration,  as  speciﬁed  in  the  package  insert);  off-label  (drugs
prescribed  for  different  ages,  at  higher  or  lower  doses,  with
different  dosing  frequency  and  administration  manner  other
than  the  indicated)18;  and  not  licensed  for  children  (drugs
for  which  there  was  no  information  or  were  contraindicated
for  children,9 registration  and  labeling  only  considered  the
adult  use).
The  Anatomical  Therapeutic  Chemical  Classiﬁcation
(ATC)19 was  used  to  enable  the  analysis  of  drugs  by  thera-
peutic  classes.  Data  were  organized  in  Microsoft  Ofﬁce  Excel
2007  spreadsheet  and  analyzed  using  the  SPSS  18.0  software.
Descriptive  statistics  with  absolute  frequencies  (mean  and
standard  deviation)  was  used.
Results
Prescriptions  for  705  pediatric  patients  were  retained  in  the
study  period  in  selected  units,  generally  more  than  one  pre-
scription  per  patient.  Only  326  of  these  prescriptions  were
included  in  the  study,  as  379  records  were  not  found  or  were
incomplete.  Regarding  care  units,  203  (62.3%)  patients  were
from  the  Family  Health  Strategy  (FHS)  Itapuã  and  the  other
123  (37.7%)  from  the  Reference  Unit  (RU)  Lomba  Sabão.
Of  the  326  children,  56.4%  were  male.  There  was  a  higher
prevalence  of  infants,  142  (43.3%);  followed  by  preschool-
ers,  103  (31.6%).  Schoolers  55  (16.9%)  and  adolescents  27
(8.3%)  were  minority  and  amounted  to  25.2%  of  the  patients.
Among  infants  (0--2  years),  89  (63%)  were  up  to  12  months
old  and  53  (37%)  from  13  months  to  2  years  old.  The  num-
ber  of  drugs  ranged  from  one  to  eight,  with  an  average
of  2.2±1.4  per  patient.  According  to  the  analysis  of  pre-
scriptions,  95.4%  of  all  prescribed  drugs  belonged  to  the
municipal  list  of  essential  medicines  (RESUME).In  total,  39  different  active  principles  (30  isolates  and  9
combinations)  were  prescribed  in  different  presentations.
The  most  frequently  prescribed  drugs  were:  paracetamol
88  (11.8%);  nasal  saline  81  (11.1%);  loratadine  80  (10.3%);
T
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moxicillin  66  (8.3%);  prednisolone  60  (8.2%),  and  oral  spray
albuterol  53  (7.3%).  Table  1  describes  the  frequency  of  pre-
cription  by  therapeutic  class.
We  found  731  prescribed  drugs.  There  was  no  prescrip-
ion  of  unlicensed  drugs  for  children.  All  prescribed  drugs
ere  for  adult  and  pediatric  use.  Of  the  total,  232  (31.7%)
rescriptions  were  off-label  and  13  (0.02%)  had  no  speciﬁ-
ation  of  the  prescribed  dose,  only  the  name  of  the  active
ngredient.  Drugs  not  specifying  the  dose  were:  vitamin  A+D
nd  permethrin  (for  9  [1.2%]  and  4 [0.6%]  children,  respec-
ively).  The  classiﬁcation  of  prescribed  drugs  is  summarized
n  Table  2.
Among  the  off-label  prescriptions,  the  following  types
nd  frequencies  were  seen:  off-label  dose,  90  (38.8%);  fol-
owed  by  age,  73  (31.5%);  and  frequency  of  administration,
8  (29.3%).  Regarding  off-label  dose,  overdosing  was  more
revalent  than  underdosing:  84  (93.3%)  vs.  6  (6.7%)  prescrip-
ions,  respectively.
The  off-label  prescribed  drugs  are  presented  in  Table  3  by
herapeutic  classes.  Among  them,  we  highlight  loratadine,
ral  spray  salbutamol,  fenoterol,  and  dimethicone.
Loratadine  was  the  third  most  prescribed  drug  and  had
 frequency  of  off-label  prescription  of  85.3%,  dosing  fre-
uency  of  53.1%,  younger  age  than  the  recommended  of
5%,  and  overdosing  of  21.9%.  Regarding  prescriptions  for
ff-label  frequency  of  administration,  19  (55.9%)  were  also
ff-label  dose;  that  is,  two  types  of  discordant  recom-
ended  use.
Salbutamol,  whose  frequency  of  prescription  was  7.3%
53)  was  prescribed  off-label  in  100%  of  prescriptions:  indi-
ated  for  an  age  group  younger  than  the  recommended  in
7  (50.9%)  and  for  use  in  doses  higher  than  recommended  in
he  package  insert  in  26  (49.1%)  cases.
Fenoterol  had  18  prescriptions.  Only  one  of  them  was  in
ccordance  with  the  package  insert,  the  other  17  (94.4%)
ere  classiﬁed  as  off-label.  Of  these,  15  (88.2%)  were
ff-label  for  frequency  of  administration  above  the  rec-
mmended  and  two  (11.8%)  due  to  the  higher  dose  than
ecommended.  The  two  prescriptions  with  dose  higher  than
ecommended  also  had  frequency  of  administration  above
he  recommended.
Dimethicone,  a  medication  out  of  the  municipal  list  of
ssential  medicines,  was  prescribed  in  17  occasions,  16  of
hem  (94.1%)  off-label:  14  for  frequency  of  administration
bove  the  recommended  and  twice  for  overdosing.  In  both
ases  of  overdosing  there  was  also  the  incorrect  prescribing
f  frequency  of  administration.
In  the  analysis  of  off-label  prescribed  drugs  by  age  group,
t  is  noteworthily  the  prescription  of  loratadine  and  dex-
hlorpheniramine  for  infants----an  age  group  for  which  these
rugs  are  not  recommended.  In  the  group  of  preschoolers,
t  is  worth  noting  the  prescription  of  salbutamol  and  amoxi-
illin  at  doses  higher  than  recommended.  In  the  age  groups
orresponding  to  schoolers  and  adolescents,  the  overdose  of
albutamol  was  what  stood  out.
iscussionhere  was  no  prescription  of  unlicensed  drugs.  Other  authors
ound  percentages,  which  varied  from  0.3  to  16.8%.5,14,18 The
bsence  of  unlicensed  drugs  is  relevant  and  may  be  related
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Table  1  Therapeutic  class  of  prescribed  drugs  and  prescription  frequency.
ATC  group  Class  Drugs  (number  of  prescriptions)  Prescriptions,  n  (%)
N02  Analgesics,  antipyretics  Paracetamol  (88),  dipirone  (7),  ibuprofen  (26)a 121(16.6%)
R03 Drugs  used  in  obstructive
respiratory  diseases
Beclomethasone  (40),  disodium  cromoglycate  (1),
fenoterol  (18),  salbutamol  (53),  budesonide  (1)
113  (15.5%)
R01 Nasal  preparations  Budesonide  (4),  sodium  chloride  (81),
beclomethasone  (24)
10  (14.9%)
R06 Systemic  antihistamines  Loratadine  (80),  dexchlorpheniramine  (8),
brompheniramine  (1)
89  (12.2%)
J01 Systemic  antimicrobials  Amoxicillin  (66),  cephalexin  (6),
sulfamethoxazole+trimethoprim  (2),
metronidazole  (1)
75  (10.3%)
H02 Systemic  corticosteroids Prednisolone  (60),  prednisone  (12) 72  (9.9%)
P02 Antiparasitics,  anthelmintics  Albendazole  (19),  ivermectin  (1),
mebendazole  (12)
32  (4.4%)
A03 Drugs  used  in  gastrointestinal
disorders
dimethicone  (18),  metoclopramide  (7),
bromopride  (4)
29  (4.0%)
B03 Antianemics  Ferrous  sulphate  (21) 21  (2.9%)
D07 Topical  corticosteroids Dexamethasone  (17),  desonide  (1) 18  (2.5%)
D01 Topical  antifungal miconazole  (11) 11  (1.5%)
A011 Vitamins Vitamin  A+D  (10) 10  (1.4%)
D06 Topical  antimicrobials Neomycin+bacitracin  (8) 8  (1.1%)
S02 Otologic  drugs Borate  8-hydroxyquinoline  trolamine  (5),
neomycin  +  polymyxin+hydrocortisone  (1)
6  (0.8%)
A01 Stomatological  preparations  Nystatin  (5)  5  (0.7%)
P03 Ectoparasiticides/scabicides  Permethrin  (4)  4  (0.6%)
A07 Antidiarrheals,  antimicrobial
agents
Oral  rehydration  salts  (3),  Saccharomyces
boulardii  (1)
4  (0.6%)
A06 Constipation  drugs  Lactulose  (2)  2  (0.3%)
M01 Antiinﬂammatory  Nimesulide  (1)  1  (0.1%)
D02 Emollients  and  protectors  Zinc  oxide  (slurry  water)  (1)  1  (0.1%)
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iATC, anatomical therapeutic chemical classiﬁcation.
a Ibuprofen prescribed as an analgesic and antipyretic.
o  the  high  adherence  (95.4%)  of  Viamão  pediatricians  to  the
ist  of  essential  medicines  in  the  municipality  (RESUME).  A
ower  percentage  of  adherence  to  the  RESUME  (76.4%)  was
een  in  a  study  performed  in  eight  cities  of  three  Brazilian
tates.20 The  use  of  lists  of  essential  medicines  is  a  measure
ecommended  by  the  World  Health  Organization  to  promote
he  rational  use  of  drugs.21 The  availability  of  a  smaller  ther-
peutic  arsenal  and  that  takes  into  account  the  health  needs
f  the  majority  of  the  population  can  reduce  the  chance  of
sing  unlicensed  products.
On  the  other  hand,  the  prescription  of  off-label  drugs
n  primary  care  in  Viamão  was  high,  with  a  frequency
Table  2  Classiﬁcation  of  prescribed  drugs  regarding  its
package  insert  speciﬁcation.
Classiﬁcation  Frequency,  n  (%)
According  to  speciﬁcation  486  (66.5%)
Unlicensed  0
Off-label  prescribing  232  (31.7%)
Unable to  classifya 13  (1.8%)
Total drugs  prescribed  731  (100%)
a Unable to classify because there was no pharmaceutical form
on prescription.
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df  31.7%  above  the  range  found  in  other  European
opulation-based  studies:  Scotland  (24.6%),  England  (16%),
etherlands  (20.3%),  Estonia  (31%),  Italy  (17%),  and  France
29%).6,8,13,15,22,23 The  main  types  of  off-label  prescription  in
his  study  were  dose  (38.8%),  age  (31.5%),  and  frequency
f  administration  (29.3%).  Similarly,  the  above-mentioned
uropean  studies  indicated  dose  and  age  as  the  main  types
f  off-label  use,  in  that  order.  The  frequency  of  drug  admin-
stration  was  not  among  the  off-label  types,  which  probably
s  due  to  the  fact  that  other  authors  evaluated  the  dose
nd  frequency  of  administration  together  and  classiﬁed  the
ases  out  of  speciﬁcation  as  off-label  dose.
Overdosing  was  more  frequent,  unlike  reported  by  other
uthors  who  found  a  greater  number  of  underdosing,  par-
icularly  for  the  class  of  antimicrobial  drugs  for  systemic
se.13,14,24 There  was  a  prevalence  of  10.3%  of  antimicro-
ial  prescriptions,  which  represented  10.8%  of  total  off-label
rescriptions,  mostly  by  overdosing.  This  result  shows  a
ifferent  trend  from  that  of  other  studies  associating  under-
osing  with  physicians  difﬁculty  to  adjust  the  dose  to  the
hild’s  age,  that  is,  to  know  the  age  and  certain  situa-
ions  in  which  doses  should  be  increased.24 Amoxicillin,  the
ost  prescribed  antimicrobial  in  this  study,  has  a  dose  indi-
ation  on  label  less  than  that  of  other  sources,  such  as
he  Formulário  Terapêutico  Nacional.25 The  data  suggest  a
owngrade  of  the  package  insert  published  in  the  ANVISA
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Table  3  Type  of  off-label  use  by  therapeutic  class.
ATC  group  Class  Dose  (n=90)  Age  (n=73)  Dosing  interval
(n=68)
Form  of  administration
(n=1)
R06  Systemic  antihistamines 17  (7.3%) 22  (9.5%)  36  (15.5%)
R03 Drugs  used  in  obstructive
respiratory  diseases
28  (12.1%)  30  (12.9%)  15  (6.5%)
J01 Systemic  antimicrobials  25  (10.8%)
A03 Drugs  used  in  gastrointestinal
disorders
2  (0.9%)  7  (3.0%)  15  (6.5%)
R01 Nasal  preparations  1  (0.4%)  8  (3.5%)  1  (0.4%)
N02 Analgesics,  antipyretics  5  (2.2%)  3  (1.3%)
B03 Antianemics  4  (1.7%) 1  (0.4%)
H02 Systemic  corticosteroids 3  (1.3%)
P02 Antiparasitics,  anthelmintics  2  (0.9%)
M01 Anti-inﬂammatory  1  (0.4%)  2  (0.9%)  1  (0.4%)
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Percentage of total off-label prescribing (232); ATC, anatomical t
Electronic  Labeling  and  reinforce  the  need  to  constantly
update  this  source  of  information  on  the  part  of  manu-
facturers  and  the  product  license  review  by  the  agency.
Another  important  measure  would  be  to  establish  a  munic-
ipal  Pharmacy  and  Therapeutics  Committee  aiming  at  the
development  of  protocols  for  the  use  of  the  medicines  in
the  list  according  to  recent  studies,  to  support  the  pre-
scriber  and  promote  the  rational  use  of  medicines.  It  is
worth  remembering  that  the  quality  of  drug  therapy  is  not
necessarily  related  to  the  drug’s  regulatory  status.
The  most  commonly  prescribed  off-label  drugs  were
the  anti-asthmatics  and  antihistamines  for  systemic  use
(Table  3).  These  classes  of  drugs  are  among  the  most
commonly  prescribed  in  pediatric  primary  care.6,16 In  this
study,  loratadine  was  prescribed  off-label  in  85.3%  of  cases
regarding  frequency  of  administration  (53.1%),  lower  than
recommended  age  group  (25%),  and  overdosing  (21.9%).
Considering  that  the  drug’s  plasma  half-life  is  17--24h,25
there  would  be  no  need  or  indication  for  multiple  daily
doses,  as  observed  in  this  study.  The  use  of  antihistamines
in  a  way  not  appropriate  for  the  age  has  been  reported
in  recent  literature  review  that  showed  a  variation  of
6.5--43%.26 Da  Costa  et  al.  reported  Loratadine  as  one  of
the  drugs  hard  to  deal  with  in  pediatrics  due  to  the  restric-
tion  for  age  under  2  years.1 The  usual  of  Loratadine  is  5mg
for  children  2--6  years  old  and  under  30kg  and  10mg  once-
daily  for  children  over  6  years  old  and  adults.25,26 The  study
showed  overdosing  in  prescriptions  of  loratadine.  Only  one
study  advocated  the  use  of  a  higher  dose  than  that  required
in  the  package  insert  for  treating  allergic  asthma.27 Consid-
ering  that  such  information  is  not  conﬁrmed  in  the  2012
Guidelines  of  the  Brazilian  Society  of  Pneumology  and  Phthi-
siology  for  the  Management  of  Asthma  (Sociedade  Brasileira
de  Pneumologia  e  Tisiologia  para  o  Manejo  da  Asma),  it  is  evi-
dent  the  need  for  continuing  education  of  professionals  and
dose  standardization  based  on  clinical  trials  and,  if  none,
observational  studies.28
There  was  a  prevalence  of  off-label  prescribing  of  31.5%
for  respiratory  disease  management  (Table  3),  salbutamol
spray  and  fenoterol  nebulizer  solution  standed  out  among
the  medications.  Treatment  of  asthma  in  children  is  chal-
lenging  and  often  an  overlap  between  recurrent  wheezing
d
s
b
d1  (0.4%)
eutic chemical classiﬁcation.
nd  asthma  phenotypes  occurs,  making  diagnostic  and  ther-
peutic  decisions  controversial.28 Recommendations  of  the
razilian  Society  of  Pneumology  and  Phthisiology  (SBPT)  dif-
er  from  the  package  insert  recommendations  for  salbutamol
pray.  The  guidelines  indicate  the  use  in  children  over  5  years
ld  and  with  higher  doses  than  those  indicated  by  the  man-
facturer,  even  with  possible  limitations  to  the  correct  use
f  the  device  in  this  age  group.  The  drug  package  insert
ighlights  the  difﬁculty  of  the  device  correct  use  in  children
nder  7  years,  with  no  restrictions  for  use  above  this  age
roup.  Considering  the  large  number  of  hospitalizations  and
he  risks  of  non-treatment  of  an  asthma  attack  (suffocation
s  the  leading  cause  of  death  in  almost  all  cases),28 adapt-
ng  the  adult  dose  for  children  is  a  recurring  practice  based
n  clinician’s  knowledge,  but  with  little  documentation  by
razilian  physicians.25 Although  the  clinical  beneﬁt  of  these
rugs  in  acute  asthma  management  is  well  documented,
here  is  great  variability  in  the  doses  used,  mostly  based  on
xpert  opinion,  clinical  consensus,  or  studies  with  a  limited
umber  of  patients.  Little  evidence  precisely  support  the
oses  to  be  used.28
The  use  of  salbutamol,  a  beta-adrenergic  agonist,  in  high
oses  is  associated  with  tremors,  agitation,  hypokalemia,
nd  cardiac  arrhythmias.  There  is  evidence  that  treatment
ith  salbutamol  shifts  the  cardiovascular  autonomic  regula-
ion  to  a  new  level,  characterized  by  a greater  sympathetic
esponse  and  mild  2-receptor  tolerance.  Based  on  this
vidence,  salbutamol  abuse  may  be  a  substrate  for  atrial
brillation.29
The  most  important  determinant  of  the  daily  dosage  is
linical  judgment  of  the  patient’s  response  to  treatment.
he  doctor  should  monitor  the  patient’s  response  and  adjust
he  dose  according  to  the  level  of  asthma  control.  Low,
edium  or  high  doses  settings  are  based  on  manufacturers’
harmacokinetic  and  pharmacodynamic  studies,  which  are
arely  based  on  dose-response  curves.  They  vary  according
o  the  device  used  and  must  be  assessed  individually.28
It  is  noteworthy  the  fact  that  some  prescriptions  had  no
osage,  only  the  name  of  the  drug.  For  the  patient,  pre-
cription  is  an  important  support  in  the  treatment  and  to
e  effective  it  should  have  the  basic  items,  including  the
osage.30
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Most  medicines  used  by  children  are  prescribed  in  pri-
ary  care,  and  pediatricians  or  general  practitioners  use
 relatively  small  number  of  drugs  to  solve  the  most  com-
on  problems.  The  small  cast  of  medicines  facilitates
he  development  of  municipal  clinical  protocol,  built  in
 multidisciplinary  way  in  the  Pharmacy  and  Therapeutics
ommittee.  This  contrasts  with  secondary  care  in  which  the
umber  of  children  is  lower  compared  to  the  general  popu-
ation,  but  a  much  larger  number  of  drugs  is  prescribed  to
reat  rare  and  more  serious  conditions.13
Extrapolation  of  this  study’s  results  should  be  done  with
aution,  as  data  refer  to  two  health  units,  a  ﬁve-month
eriod,  and  half  of  the  prescriptions  could  not  be  assessed
ue  to  lack  of  information.  Prescribing  habits  vary  accord-
ng  to  the  formation  of  pediatricians,  protocols,  or  even
ervice  routines.  Studies  involving  a  larger  number  of  health
nits  are  needed  to  establish  more  accurately  the  extent
f  off-label  prescribing  in  municipal  or  regional  level.  Fur-
hermore,  the  limitations  inherent  in  retrospective  studies
hould  be  considered.  Information  was  collected  from  pre-
criptions  retained  in  pharmacies  and  manual  records.  The
ncomplete  record  of  the  name  of  patients  and  the  differ-
nt  criteria  of  cataloging  records  determined  the  exclusion
f  some  cases.  The  retrospective  data  collection  also  pre-
ented  the  analysis  of  off-label  usage  by  indication,  as
his  data  was  rarely  found  in  medical  records  or  patients’
harts.  We  should  also  consider  that  only  the  prescrip-
ions  dispensed  are  retained  in  the  pharmacies  of  these
nits.  Patients  may  have  received  other  prescription  of  drugs
ubject  to  special  control,  not  present  in  REMUME,  or  of  spe-
ial  or  specialized  component  of  the  pharmaceutical  care.
espite  these  limitations,  this  study  brings  contributions,  as
he  Brazilian  data  on  the  use  of  unlicensed  and  off-label
edicines  in  children  are  so  far  restricted  to  hospitals.
The  difﬁculties  related  to  research  with  children  foster
ff-label  prescribing.  Although  this  practice  is  not  illegal,  it
reates  uncertainty  regarding  the  possible  adverse  effects
n  a  population  with  speciﬁc  characteristics  such  as  the
ediatric  population.  The  present  study  showed  that  this
ractice  is  common  in  primary  health  care  in  a  city  of  Rio
rande  do  Sul,  similar  to  studies  in  European  cities.  We  hope
hat  the  results  may  contribute  to  the  planning  of  actions  to
upport  prescribers  and  provide  greater  security  in  the  use
f  medicines  for  pediatric  patients.
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